RCT: In patients with Type 2 Diabetes, Tirzepatide is associated with reduced weight, improved glycemic control, and lower risk of hypoglycemia compared to insulin glargine.

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Related:

RCT: Once-weekly tirzepatide vs. once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes.

RCT: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2.

RCT: Tirzepatide yielded greater glycated hemoglobin and body weight reductions compared to Semaglutide 1 mg.